How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
40
CGEN Quote, Financials, Valuation and Earnings
Last price:
$1.98
Seasonality move
:
-2.67%
Day range:
$1.94 - $2.03
52-week range:
$1.13 - $2.66
Dividend yield:
0%
P/E ratio:
55.83x
P/S ratio:
26.05x
P/B ratio:
4.16x
Volume:
291.8K
Avg. volume:
566.2K
1-year change:
-14.85%
Market cap:
$182.4M
Revenue:
$27.9M
EPS (TTM):
-$0.30
Analysts' Opinion
-
Consensus RatingCompugen Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.80, Compugen Ltd. has an estimated upside of 197.44% from its current price of $1.95.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $1.95.
Fair Value
-
According to the consensus of 5 analysts, Compugen Ltd. has 197.44% upside to fair value with a price target of $5.80 per share.
CGEN vs. S&P 500
-
Over the past 5 trading days, Compugen Ltd. has underperformed the S&P 500 by -8.41% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Compugen Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Compugen Ltd. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Compugen Ltd. reported revenues of $1.9M.
Earnings Growth
-
Compugen Ltd. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Compugen Ltd. reported earnings per share of -$0.07.
Enterprise value:
99.3M
EV / Invested capital:
--
Price / LTM sales:
26.05x
EV / EBIT:
3.52x
EV / Revenue:
14.38x
PEG ratio (5yr expected):
-0.08x
EV / Free cash flow:
-0.69x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
3.52x
Gross Profit (TTM):
$513K
Return On Assets:
-24.73%
Net Income Margin (TTM):
-400.1%
Return On Equity:
-51.8%
Return On Invested Capital:
-49.12%
Operating Margin:
-417.4%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $7.5M | $59.9M | $6.9M | $17.1M | $1.9M | |
| Gross Profit | $6.5M | $50.6M | $513K | $13.5M | $241K | |
| Operating Income | -$34.5M | $10.6M | -$32.2M | $4.5M | -$7.9M | |
| EBITDA | -$34.5M | $10.6M | -- | $4.5M | -- | |
| Diluted EPS | -$0.36 | $0.02 | -$0.30 | $0.01 | -$0.07 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $112.3M | $91M | $60.3M | $114.8M | $88.9M | |
| Total Assets | $121.3M | $99.4M | $67.6M | $123.5M | $97.8M | |
| Current Liabilities | $15.3M | $14.8M | $10.4M | $27.8M | $20.3M | |
| Total Liabilities | $22.5M | $19.5M | $14.4M | $63M | $54M | |
| Total Equity | $98.8M | $79.8M | $53.2M | $60.5M | $43.8M | |
| Total Debt | $2.8M | $1.4M | $818K | $2.5M | $2.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2021-06-30 | 2022-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$13.6M | -$20.7M | |
| Cash From Investing | -- | -- | -- | $13.4M | $20.2M | |
| Cash From Financing | -- | -- | -- | $909K | $353K | |
| Free Cash Flow | -$51.4M | -$49.9M | -$62.9M | -$13.8M | -$20.9M | |
CGEN
Sector
Market Cap
$182.4M
$25.9M
Price % of 52-Week High
73.31%
51.6%
Dividend Yield
0%
0%
Shareholder Yield
0.01%
-1.66%
1-Year Price Total Return
-14.85%
-18.99%
Beta (5-Year)
2.847
0.485
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.11
200-day SMA
Buy
Level
$1.59
Bollinger Bands (100)
Buy
Level
1.43 - 1.89
Chaikin Money Flow
Sell
Level
-2M
20-day SMA
Buy
Level
$1.89
Relative Strength Index (RSI14)
Buy
Level
54.24
ADX Line
Buy
Level
37.23
Williams %R
Neutral
Level
-55.8442
50-day SMA
Buy
Level
$1.69
MACD (12, 26)
Buy
Level
0.12
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
2.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.8715)
Sell
CA Score
(Annual)
Level (-0.8964)
Buy
Beneish M-Score
(Annual)
Level (-5.8499)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (1.3573)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.
Stock Forecast FAQ
In the current month, CGEN has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CGEN average analyst price target in the past 3 months is $5.80.
-
Where Will Compugen Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Compugen Ltd. share price will rise to $5.80 per share over the next 12 months.
-
What Do Analysts Say About Compugen Ltd.?
Analysts are divided on their view about Compugen Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Compugen Ltd. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Compugen Ltd.'s Price Target?
The price target for Compugen Ltd. over the next 1-year time period is forecast to be $5.80 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CGEN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Compugen Ltd. is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CGEN?
You can purchase shares of Compugen Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Compugen Ltd. shares.
-
What Is The Compugen Ltd. Share Price Today?
Compugen Ltd. was last trading at $1.98 per share. This represents the most recent stock quote for Compugen Ltd.. Yesterday, Compugen Ltd. closed at $1.95 per share.
-
How To Buy Compugen Ltd. Stock Online?
In order to purchase Compugen Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get CGEN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CGEN
Sector
P/E ratio
55.83x
23.82x
PEG ratio
-0.08x
-0.01x
P/B ratio
4.16x
1.83x
Price / LTM sales
26.05x
1.56x
Growth Metrics
CGEN
Sector
Revenue growth
-88.96%
4.18%
Earnings growth
-625.35%
9.66%
Revenue (5-year growth)
13.45%
6.28%
Earnings forecast
$0.14
-$0.18
Profitability
CGEN
Sector
Profitability FY 2024
$19.9M
$3.1M
Return on invested capital
-49.12%
-32.89%
Return on assets
-24.73%
-29.56%
Return on equity
-51.8%
-38.66%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Mar
3
Estimated Next Earnings Date
Feb
9
Balance Sheet
CGEN
Sector
Total cash
$86.1M
$25.2M
Short term investments
$85M
$25.1M
Total assets
$115M
$73M
Long term debt
$2.5M
$3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
48
SANM alert for Jan 29
Sanmina Corp. [SANM] is up 6.61% over the past day.
Buy
72
BNAI alert for Jan 29
Brand Engagement Network, Inc. [BNAI] is up 20.87% over the past day.
Buy
58
AAOI alert for Jan 29
Applied Optoelectronics, Inc. [AAOI] is up 20.97% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
